Secuenciación en cáncer de mama avanzado HER2+ - page 24

Perez E, Breast Cancer Res 2016
ORR
64%:
CR 11,2%
PR 52,9%
SD
19,1%
PFS
12,5 m (10,4 – 16,8)
TTP
12,9m (10,5 – 16,8)
N 106
>ER+ y enf visceral vs Cleop.
Tz previo 41% (vs 11% Cleop.)
1º endpoint ORR
Diarrea 57,5% (vs 66,8 Cleop.)
Alopecia 23,6% (vs 60,9% Cleop.)
Neutropenia 50,9 %
Neutropenia g3/4 31,1% (vs 48,9% Cleop)
FN 5,7% (vs 13,8% Cleop)
1...,14,15,16,17,18,19,20,21,22,23 25,26,27,28,29,30,31,32,33,34,...60
Powered by FlippingBook